As a third application case, we selected data for a set of 26 breast cancer cell lines from the CCLE resource and studied their differential responses to lapatinib, a clinically approved dual EGFR and ERBB2 (HER2) kinase inhibitor. Here, EGFR is linked to breast cancer.